ECONOMIC COSTS OF BENIGN PROSTATIC HYPERPLASIA IN THE PRIVATE SECTOR

Treatment of men with BPH places a significant burden on employees and their employers through direct medical costs as well as through lost work time. Direct and indirect costs to the private sector related to BPH treatment are estimated to be $3.9 billion.